A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

L. G. Feun; J. A. Blessing; R. J. Barrett; P. Hanjani

doi:10.1097/00000421-199312000-00010

A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

L. G. Feun, J. A. Blessing, R. J. Barrett, P. Hanjani

Medicine

Research output: Contribution to journal › Article › peer-review

70 Scopus citations

Abstract

A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m² x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.

Original language	English (US)
Pages (from-to)	506-508
Number of pages	3
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	16
Issue number	6
DOIs	https://doi.org/10.1097/00000421-199312000-00010
State	Published - 1993

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-199312000-00010

Cite this

A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix : A Gynecologic Oncology Group study. / Feun, L. G.; Blessing, J. A.; Barrett, R. J.; Hanjani, P.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 16, No. 6, 1993, p. 506-508.

Research output: Contribution to journal › Article › peer-review

@article{bf44b70a8b10472fa8185e68acbc2db3,

title = "A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study",

abstract = "A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.",

author = "Feun, {L. G.} and Blessing, {J. A.} and Barrett, {R. J.} and P. Hanjani",

year = "1993",

doi = "10.1097/00000421-199312000-00010",

language = "English (US)",

volume = "16",

pages = "506--508",

journal = "American Journal of Clinical Oncology",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix

T2 - A Gynecologic Oncology Group study

AU - Feun, L. G.

AU - Blessing, J. A.

AU - Barrett, R. J.

AU - Hanjani, P.

PY - 1993

Y1 - 1993

N2 - A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.

AB - A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.

UR - http://www.scopus.com/inward/record.url?scp=0027333359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027333359&partnerID=8YFLogxK

U2 - 10.1097/00000421-199312000-00010

DO - 10.1097/00000421-199312000-00010

M3 - Article

C2 - 8256767

AN - SCOPUS:0027333359

VL - 16

SP - 506

EP - 508

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -

A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this